Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Kelvin Kar-Wing ChanHelen GuoSierra ChengJaclyn M BecaRuby Redmond-MisnerWanrudee IsaranuwatchaiLucy QiaoCraig EarleScott R BerryJames J BiagiStephen WelchBrandon M MeyersNicole MittmannNatalie CoburnJessica AriasDeborah SchwartzWei F DaiScott GavuraRobin McLeodErin Diane KennedyPublished in: Cancer medicine (2019)
In the real world, FFX had longer OS, less frequent all-cause EDV and all-cause hospitalization, but more febrile neutropenia-related hospitalization compared to GnP.